JNJ16567083 (EMQMCM) is a potent and selective mGluR1 antagonist that shows neuroprotective effects in some hypoxia-ischemia models.

JNJ-10198409 is a highly potent, selective PDGFRβ inhibitor with IC50 of 4.2 nM.

JNJ 39220675 is potent and selective, brain penetrant H3 antagonist with Ki of 1.4 nM, pA2 of 9.42 for hH3.

JNJ 10181457 is a neutral, potent and selective, brain penetrant H3 antagonist with pKi of 8.93, pA2 of 9.22 for hH3.

JNJ 10181457 is a neutral, potent and selective, brain penetrant H3 antagonist with pKi of 8.93, pA2 of 9.22 for hH3.

JNc-440 is a small molecule that significantly and specifically strengthens the TRPV4-KCa2.3 interaction in mouse endothelial cells, but does not systemically activate TRPV4 and KCa2.3.

JM6 (KMO inhibitor JM6) is an orally bioavailable small-molecule prodrug of Ro 61-8048, which is an inhibitor of kynurenine 3-monooxygenase (KMO).

JKA3 inhibitor 31 is a highly potent, selective, reversible, covalent JAK3 inhibitor with IC50 of 49 nM, shows no activity against other JAK kinases.

JI130 (JI-130) is a specific Hse1 inhibitor that inhibits the cancer-associated transcription factor Hes1 via the PHB2 chaperone, blocks Hes1-mediated transcriptional repression.

JH-XI-10-02 is a CDK8 PROTAC based on the CDK8 inhibitor JH-VIII-49, induces partial degradation of CDK8 in Jurkat cells with IC50 of 159 nM..

JH-VIII-49 is a potent and selective inhibitor of CDK8 with IC50 of 16 nM, also inhibits CDK19 (IC50=8 nM).

JH-T4 is a potent small molecule SIRT2 inhibitor with IC50 of 0.3 uM (sirtuin deacylation activity), increase intracellular K-Ras4a lysine fatty acylation.

JH-IX-179 is a novel highly potent and selective type I ATP competitive pan-FLT3 inhibitor with IC50 of 4 and 10 nM for FLT3-ITD and D835Y, respectively.

JF5 (PAR1 inhibitor JF5) is an allosteric inhibitor of PAR1 that binds to helix 8 of the receptor.

JCR 795b is a competitive, small molecule inhibitor of choline kinase (ChoK) with in vitro IC50 of 3.5 uM.

JCP251 is a selective small molecule inhibitor of S. aureus serine hydrolase FphB, effectively reduces infectivity in vivo..

JC-171 is a selective NLRP3 inflammasome inhibitor that inhibits LPS/ATP-induced IL-1β release from macrophages with IC50 of 8.45 uM.

JBJ-01-162-04 is a small molecule targeting the flavivirus E protein with broad-spectrum activity, shows activity against DENV in the infectivity assay with IC90 of 0.1 uM.

JAS239 is a novel carbocyanine dye that binds and competitively inhibits choline kinase (ChoK) intracellularly, prevents choline phosphorylation and induces cell death in breast cancer cell lines.

JAK-IN-35 is a potent and efficacious dual JAK1/JAK3 inhibitor with IC50 of 0.9/1.9 nM.

JAK3-IN-1 is a potent and selective JAK3 inhibitor with IC50 of 4.8 nM.

JAK3i is a selective, covalent JAK3 kinase inhibitor with IC50 of 0.43 nM, shows high selectivity (>3,000-fold) against the closely related kinase domains in JAK1, JAK2, or TYK2, displays 1,300-fold, 600-fold, and 50-fold over EGFR, ITK, and BTK respectiv

JAK1-IN-31 is a potent and selective JAK1 inhibitor with Ki of 1.9 nM, less potent for JAK3 (Ki=280 nM) and Tyk2 (Ki=12 nM) and no inhibition on hERG and CYP3A4 (IC50>10 uM).

J-113397 is a potent, selective nociceptin/orphanin FQ receptor (NOP receptor/ORL1) antagonist with IC50 of 2.3 nM.

Ivacaftor (VX-770, VX770) is a potent, orally bioavailable CFTR potentiator, increases G551D- and F508del CFTR-mediated Cl- secretion with EC50 of 100 nM.

Ivacaftor (VX-770, VX770) is a potent, orally bioavailable CFTR potentiator, increases G551D- and F508del CFTR-mediated Cl- secretion with EC50 of 100 nM.

ITZ-1 is a client-selective Hsp90 inhibitor that efficiently induces heat shock factor 1 (HSF1) activation, selectively inhibits IL-1β-induced MMP-13 production (IC50=0.51 uM) via inhibition of ERK activation.

ITX-5061 is a scavenger receptor B1 antagonist that promotes high-density lipoprotein (HDL) levels.

ITI-214 is a potent, selective, orally active phosphodiesterase 1 (PDE1) inhibitor with Ki of 58 pM, displays >1,000-fold selectivity over PDE4A/4D and other PDE isoforms.

Istaroxime(PST2744) is a positive inotropic agent that mediates its action through inhibition of sodium/potassium adenosine triphosphatase (Na+/K+ ATPase).